

URGENT
PRESS RELEASE



Wockhardt Limited
Wockhardt Towers
Bandra Kurla Complex
Bandra (East), Mumbai 400 051,
India
Tel.: +91 22 2653 4444
Fax: +91 22 2653 4242
Website: www.wockhardt.com

Wockhardt's 15 months Sales stood at Rs. 4,501 crores and Operating Profit at Rs. 823 crores

Mumbai, 20 May,2010

Pharmaceutical and Biotechnology major Wockhardt Limited today announced its audited results for the period ending March 31, 2010. During these 15 months period (Jan 2009 – Mar 2010), the revenue was Rs. 4,501 crores and operating profit (EBIDTA) was Rs. 823 crores.

For the quarter (Jan-March 2010) under review, the sales revenue was Rs. 872 crores and operating profit (EBITDA) was Rs. 158 crores. The net loss for the quarter was Rs. 565 crores. This included the derivatives related losses and non-cash provisions for impairment of Negma's goodwill due to the possible threat of generics to its principal product amounting to Rs. 633 crores. There was also an exchange fluctuation loss of Rs. 16 crores

Highlights of the Quarter (Jan-Mar 2010) Results:

India Business:

Wockhardt's India branded business grew by 24% in Jan-Mar 2010 over the corresponding period of 2009. The Nutrition business grew by 20%. Overall 8 brands featured in the list of 'Top 300' brands of the industry with 2 brands in the 'Top 100'. Wockhardt's Power Brands is showing good consistent growth of over 26%.

Europe Business:

Wockhardt UK grew by 19% compared to the industry growth of only 5% in Jan-Mar 2010 over the corresponding period of 2009. Growth drivers being Hospital products that grew by 16% and exports by 31%. The CRAMS business grew by 23% over the same period. Pinewood Healthcare's domestic business is back on track after its sluggish growth in 2009 and has maintained a market share of 29% during the same period. Two new products, Losartan and Grepid were launched and exports were up by 7% for Pinewood. Negma Laboratories' Nebilox grew by 4% during the same period.

USA Business:

Wockhardt's Morton Grove Pharmaceuticals business has shown a robust 40% growth in Jan-Mar 2010 over the corresponding period of 2009. Wockhardt USA received 3 ANDA approvals and launched two new products thereby expanding its product basket to 76 in the quarter.

As per March 2010 Wolters Kluwer data, 15 products of Wockhardt USA are ranked in the Top-5 positions in the US. Also, Wockhardt's Morton Grove Pharmaceuticals has 26 products in the top slots, of which 13 are at the No.1 position and the other 13 are in the No. 2 position in their respective therapeutic groups in the US.

About Wockhardt

Wockhardt is a technology-driven global pharmaceutical and biotechnology major with an innovative multi-disciplinary research and development programme. It has 5 research centres and 14 world-class manufacturing plants dotting various countries and continents that are compliant to international regulatory standards such as the US FDA, MHRA and other global regulatory bodies. It has end-to-end integrated capabilities for its products, starting with manufacture of the oral and sterile API's, the dosage forms and marketing through its wholly owned

subsidiary in the US. Wockhardt has a global footprint including the US, UK, Ireland and France with a multi-ethnic workforce from 14 different nationalities.

**For more information, visit www.wockhardt.com
Corporate Relations Department**

For press enquiries about Wockhardt, please contact

➤ Daryl Suchitha
Associate Vice President - Corporate Relations
Wockhardt Limited
Wockhardt Towers, Bandra-Kurla Complex,
Bandra East, Mumbai 400 051, India.

Tel. : + 91 - 22 - 2653 4444. Extension: 6303
Direct Tel.: + 91 - 22 - 2659 6303
Fax: + 91 - 22 - 2653 4242
Email: daryls@wockhardt.com

Disclaimer:

The company would like to caution that any forward-looking statements or projections made by the company, including those made in the press release announcements, are subject to risks and uncertainties that may cause actual results to differ materially from those projected.